UCSF PEDIATRIC SUSCEPTIBILITY DATA 2011
N/A-testing NOT APPLICABLE to organism.
CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime,
GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole,
CIP-ciprofloxacin, MER- meropenem, P/T-piperacillin-tazobactam,
PCN-penicillin, NAF-nafcillin, ERY-erythromycin, CLIN-clindamycin,
DOX-doxycycline, VANC-vancomycin
% Strains Susceptible; Total isolates include inpatient and outpatient from UCSF and Mt. Zion Hospitals
Gram-negative isolates (tested from all sites)
|
Organism |
Total isolates |
CZOL |
CTRX |
CTAZ |
CFPM |
GEN |
TOB |
T/S |
CIP |
P/T |
MER |
| Acinetobacter baumanii | 4 | N/A | 50 | 100 | 75 | 100 | 100 | 100 | 100 | 75 | 100 |
|
5 |
N/A |
40 |
40 |
100 |
80 |
80 |
80 |
80 |
60 |
100 |
|
|
5 |
N/A |
60 |
40 |
80 |
100 |
100 |
80 |
80 |
60 |
100 |
|
|
31 |
N/A |
56 |
55 |
100 |
91 |
91 |
78 |
91 |
72 |
100 |
|
|
Urine Non-Urine |
68 47 25 |
69 68 76 |
90 91 88 |
92 100 100 |
97 98 96 |
93 96 88 |
91 94 88 |
71 74 60 |
85 89 80 |
99 98 100 |
100 |
|
15 |
67 |
100 |
100 |
100 |
100 |
93 |
100 |
100 |
100 |
100 |
|
|
19 |
84 |
95 |
100 |
100 |
89 |
95 |
79 |
95 |
95 |
100 |
|
|
6 |
50 |
100 |
100 |
100 |
100 |
100 |
50 |
100 |
100 |
100 |
|
|
PICU + ICN Non-ICU/ICN |
34 12 12 |
N/A |
N/A |
85 83 87 |
88 83 91 |
100 100 100 |
97 100 96 |
N/A |
97 100 96 |
91 83 88 |
94 92 96 |
|
8 |
N/A |
88 |
100 |
100 |
100 |
100 |
100 |
100 |
88 |
100 |
* Escherichia coli OUTPATIENT susceptibility to cefazolin/cephalexin: 85%. Outpatient TMP/SMX susceptibility is 69%. Outpatient ciprofloxacin susceptibility is 95%. Nitrofurantoin susceptibility is 98%
and should only be used for lower UTIs in patients with CrCl >60 mL/min
** Pseudomonas aeruginosa isolates do not include isolates from cystic fibrosis patients
% Strains Susceptible; Total isolates include inpatient and outpatient from UCSF and Mt. Zion Hospitals
Gram-positive isolates (tested from all sites)
|
Organism |
Total Isolates |
PCN |
NAF |
ERY |
CLIN |
CIP |
DOX |
T/S |
VANC |
|
MRSA MSSA |
121 33 96 |
5 |
79 |
59 15 60 |
78 72 86 |
83
|
94 88 89 |
95 94 94 |
100 |
|
46 |
2 |
26 |
30 |
57 |
74 |
85 |
65 |
100 |
|
|
6 |
See Below |
N/A |
50 |
83 |
N/A |
67 |
83 |
100 |
† Does not include Mt. Zion strains
N/A-testing NOT APPLICABLE to organism. PIP-piperacillin, CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime,
GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, IMI-imipenem, P/T-piperacillin-tazobactam,
PCN-penicillin, NAF-nafcillin, ERY-erythromycin, CLIN-clindamycin, DOX-doxycycline, VANC-vancomycin, AMP-ampicillin
|
Staphylococcus aureus |
Outpatient nafcillin susceptibility is 77% (Nafcillin resistance predicts cephalosporin resistance) |
|
¨ Enterococcus spp. |
Enterococcus faecalis species are 100% ampicillin susceptible. Of 23 enterococcal bacteremias in 2011, 8 were due to Enterococcus faecium, and 5 isolates (63%) were vancomycin resistant (ie 5/23 [22%] of enterococcal bacteremias were VRE). The addition of gentamicin (1 mg/kg Q8h) is required for bactericidal activity in serious systemic enterococcal infections (e.g. endocarditis). |
|
¨ Streptococcus pneumoniae |
50% (3/6 isolates) were PCN non-susceptible. 83% (5/6) isolates were susceptible to CTRX. All isolates were susceptible to levofloxacin. NOTE: For the treatment of meningitis, pending susceptibilities VANC empirically should be added to the regimen since failures (due to highly resistant isolates) have been reported with ALL third generation cephalosporins. |